Concerned about your investment in Kalytera Therapeutics, Inc.?
Are you concerned about your investment losses in Kalytera Therapeutics, Inc. ? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.
Kalytera Therapeutics, Inc. reportedly engages in the development of next generation cannabinoid therapeutics. The company filed a form D to raise capital from investors in 2016, according to filings with the SEC. The total offering amount was purportedly $2,400,000.
According to MarketWatch, as of August 31, 2020, Kalytera’s shares were down more than 99% YTD.
Filing a Complaint against your Brokerage Firm
The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.
The problem with pharmaceutical and biotech investments such as Kalytera Therapeutics, Inc. is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.
If you have concerns regarding investment losses in Kalytera Therapeutics, Inc., please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.